RedHill Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.29	-	-	61.8	85.76
Revenue Growth (YoY)	-	-	-	-27.94%	33.25%
Cost of Revenue	-	-	-	33.34	49.41
Gross Profit	0.29	-	-	28.46	36.35
Selling, General & Admin	6.17	4.89	6.02	64.03	87.99
Research & Development	2.02	1.59	3.53	7.28	29.5
Total Operating Expenses	8.2	6.48	9.55	71.31	117.49
Operating Income	7.94	6.48	9.55	42.84	81.14
Interest Income	-1.35	-8.35	-0.3	-13.56	-0.05
Interest Expense	1.46	1.51	9.25	42.39	16.66
Total Non-Operating Income (Expense)	0.11	-6.84	8.95	28.83	16.61
Pretax Income	8.05	-0.36	18.5	71.67	97.74
Net Income	0.43	8.27	-23.92	71.67	97.74
Earnings From Discontinued Operations	7.65	-8.63	42.41	-	-
Net Income to Common	0.43	8.27	-23.92	71.67	97.74
Net Income Growth	-94.81%	-	-	-26.68%	-
Shares Outstanding (Basic)	3	1	0	0	0
Shares Outstanding (Diluted)	3	1	0	0	0
Shares Change (YoY)	156.37%	375.56%	320.45%	32.46%	27.73%
EPS (Basic)	-	-	100.00	-1200.00	-2100.00
EPS (Diluted)	-	-	100.00	-1200.00	-2100.00
Shares Outstanding	5.09	1.23	1.27	0.09	0.05
Free Cash Flow	-9.66	-9.38	-35.83	-29.38	-65.16
Free Cash Flow Per Share	-3.06	-7.61	-138.28	-476.76	-1400.51
Gross Margin	100.00%	-	-	46.06%	42.39%
Operating Margin	2776.92%	-	-	69.33%	94.61%
Profit Margin	-2825.17%	-	-	115.97%	113.98%
FCF Margin	-3376.22%	-	-	-47.55%	-75.98%
EBITDA	8.35	7.09	11.54	51	99.28
EBITDA Margin	2919.93%	-	-	82.52%	115.77%
EBIT	7.94	6.48	9.55	42.84	81.14
EBIT Margin	2776.92%	-	-	69.33%	94.61%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q